Skip to content
DataLookout
Menu

Changes this week

Changes detected in the 7 days to Nov 21, 2026

  1. Notable: Virtual Reality-based Rehabilitation for Traumatic Hand and Wrist Injuries Primary endpoint(s) modified University of MalagaNot applicable NCT07633769
  2. Notable: Photobiomodulation for Reducing Sedative-Hypnotic Use:Clinical Trial of a Light-Therapy Device Enrollment increased: 60 → 90 participants National Health Research Institutes, TaiwanNot applicable NCT07764107
  3. Notable: Citicoline Eye Drops 2% on Visual Field Preservation · Open Angle Glaucoma Primary and study completion dates pushed to Jul 1, 2029 Omikron Italia S.r.l.Phase 3 NCT05710198
  4. Notable: Zasocitinib in Children and Teenagers With Plaque Psoriasis Primary and study completion pushed from Jan 24, 2033 to Jul 3, 2034 TakedaPhase 3 NCT07250802
  5. Notable: TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone · Recurrent Glioblastoma Primary completion pushed from Jul 2027 to Jul 2028 Telix Pharmaceuticals (Innovations) Pty LimitedPhase 3 NCT07100730
  6. Notable: Patients With Primary Vitreoretinal Lymphoma Primary and study completion pushed from Dec 2026 to Dec 2029 Aldeyra Therapeutics, Inc.Phase 3 NCT07402876
  7. Notable: Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules · Advanced or Unresectable Alveolar Soft Part Sarcoma Primary completion pushed from Nov 2027 to Dec 2028 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2 NCT07548177
  8. Notable: OPT101 · Type 1 Diabetes Mellitus Primary completion pushed from May 31, 2026 to May 31, 2027 Op-T LLCPhase 2 NCT06964087
  9. Notable: Intrathecally Administered Gene Therapy AMT-162 · SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) Primary completion pushed from Sep 30, 2026 to Dec 30, 2030 UniQure Biopharma B.V.Phase 1/2 NCT06100276
  10. Notable: Relacorilant in Combination With Different Treatment Regimens · Gynecological Cancers Primary completion pushed from Aug 2026 to Dec 2027 Corcept TherapeuticsPhase 2 NCT06906341
  11. Notable: NHWD-870 HCl in Adults and · Advanced NUT Cancer Primary completion pushed from Jun 30, 2025 to Mar 30, 2027 Zhejiang Wenda Pharma Technology LTD.Phase 2 NCT06527300
  12. Notable: Ablation of Arteries · Type 2 Diabetes Mellitus and Its Comorbidities Primary completion pushed from Jan 2025 to Jun 2027 Neurotronic, Inc.Phase 1 NCT05369065
  13. Notable: Arterial Ablation · Type 2 Diabetes Mellitus and Its Comorbidities Primary completion pushed from Jan 2025 to May 2027 Neurotronic, Inc.Phase 1 NCT05363761
  14. Notable: Usability of the EXPLORER Exoskeleton · Neurodevelopmental Disorders in Natural Environments Primary completion pushed from Apr 1, 2025 to Aug 1, 2026 MarsiBionicsNot applicable NCT06765070
  15. Notable: Lubricin-inspired Osteoarthritis Treatment: a Unique Solution Primary completion pushed from Jun 2027 to Mar 2028 Pleryon Therapeutics (Hangzhou) LimitedNot applicable NCT07611708
  16. Notable: Juläine (TM) · Atrophic Facial Acne Scars Primary completion pushed from Dec 2026 to Jan 2028 Nordberg Medical ABNot applicable NCT07058883
  17. Notable: Acellular Dermal Matrix Investigation in Breast Reconstruction Primary completion pushed from Dec 2026 to Dec 2027 RTI SurgicalNot applicable NCT06456554
  18. Notable: Novel Joint Distraction Knee Orthosis for Treating Medial Knee Osteoarthritis Primary completion pushed from Jun 1, 2026 to Sep 1, 2027 Icarus Medical InnovationsNot applicable NCT07439315
  19. Notable: HEARTFELT Study Primary completion pushed from Jan 1, 2028 to Dec 31, 2028 Heartfelt TechnologiesNot applicable NCT06222099
  20. Notable: Juläine™ in Improving Gluteal Skin Laxity in Adults Primary completion pushed from Apr 2027 to Jan 2028 Nordberg Medical ABNot applicable NCT07332650
  21. Notable: AccuraSee™ IOPCL for Secondary Implantation in the Capsular Bag to Improve Near and/or Intermediate Vision Following Previous Cataract Surgery Primary and study completion pushed from Mar 2026 to Dec 2027 OnPoint Vision IncNot applicable NCT06625749
  22. Notable: PGx Medication Safety Reviews · IDD Primary completion pushed from Jul 31, 2027 to Jul 31, 2028 GalenusRx, Inc.Not specified NCT07092852
  23. Notable: Multicentric Pilot Study for the Application of an Endourethral Device · Stress Urinary Incontinence Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2027 Relief srlNot applicable NCT07327528
  24. Notable: Imatinib to Increase RUNX1 Activity · Germline RUNX1 Deficiency Primary completion pushed from Oct 30, 2026 to Oct 30, 2027 National Cancer Institute (NCI)Phase 1 NCT06090669
  25. Notable: Reduced Port Laparoscopic Gastrectomy for Gastric Cancer Primary and study completion pushed from Mar 1, 2027 to Mar 1, 2029 Nanchong Central HospitalNot applicable NCT04295473